ANI Pharmaceuticals | ANIP - Operating Expenses


ANI Pharmaceuticals reported $217.93M in Operating Expenses for its fiscal quarter ending in December of 2025.





Operating Expenses Change Date
AbbVie USD 10.81B 13.45B Dec/2025
ANI Pharmaceuticals USD 217.93M 287.88M Dec/2025
Assertio Holdings USD 105.8M 12.5M Sep/2025
Aurora Cannabis CAD 129.98M 16.05M Dec/2025
Canopy Growth CAD 87.2M 6.22M Dec/2025
Eli Lilly USD 10.31B 1.09B Dec/2025
Emergent BioSolutions USD 555.9M 242.7M Jun/2023
Heron Therapeutics USD 40.55M 1.46M Dec/2025
Hikma Pharmaceutical USD 1.34B 702M Dec/2025
Knight Therapeutics CAD 126.9M 8.29M Dec/2025
Nektar Therapeutics USD 40.9M 44.19M Dec/2025
Novartis USD 9.8B 23M Dec/2025
Omeros USD 59.16M 20.13M Jun/2024
Perrigo USD 1.03B 75.3M Dec/2025
Sun Pharmaceuticals INR 111.11B 6.97B Sep/2025
Teva Pharmaceutical Industries USD 4.22B 812M Dec/2025